Breaking News

Seneca Completes Stem Cell Manufacturing Facility

Will be used to manufacture the company's lead stem cell therapy for clinical trials within China

By: Contract Pharma

Contract Pharma Staff

Seneca Biopharma, a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, has completed its new cell manufacturing facility in Suzhou, China. The facility will be used to manufacture NSI-566, the company’s lead stem cell therapy, for clinical trials within China, including a non-GCP compliant Phase II trial currently underway for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing. Stroke is the leading cause of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters